Canaccord Genuity started coverage on shares of AveXis, Inc. (NASDAQ:AVXS) in a report issued on Thursday, October 26th, MarketBeat Ratings reports. The brokerage issued a hold rating and a $110.00 target price on the stock.
AVXS has been the topic of a number of other research reports. Nomura initiated coverage on shares of AveXis in a report on Monday, August 28th. They issued a reduce rating and a $52.00 price objective on the stock. Wells Fargo & Company reissued an outperform rating on shares of AveXis in a research note on Friday, September 29th. Zacks Investment Research raised shares of AveXis from a sell rating to a hold rating in a research note on Thursday, September 7th. BMO Capital Markets reaffirmed an outperform rating and issued a $130.00 price objective (up previously from $123.00) on shares of AveXis in a research note on Thursday, October 12th. Finally, Goldman Sachs Group, Inc. (The) reiterated a buy rating and issued a $130.00 target price on shares of AveXis in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have assigned a buy rating to the stock. AveXis currently has a consensus rating of Buy and an average price target of $108.26.
AveXis (NASDAQ AVXS) traded down $3.52 on Thursday, reaching $95.79. 739,200 shares of the company were exchanged, compared to its average volume of 313,191. AveXis has a 1-year low of $44.68 and a 1-year high of $108.27.
AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the previous year, the company posted ($0.87) EPS. equities analysts anticipate that AveXis will post -5.55 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “AveXis, Inc. (NASDAQ:AVXS) Research Coverage Started at Canaccord Genuity” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/12/avexis-inc-avxs-coverage-initiated-by-analysts-at-canaccord-genuity.html.
In other news, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $101.23, for a total value of $1,518,450.00. Following the completion of the sale, the insider now directly owns 1,841,019 shares of the company’s stock, valued at approximately $186,366,353.37. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $97.25, for a total value of $173,105.00. Following the sale, the vice president now directly owns 1,780 shares of the company’s stock, valued at $173,105. The disclosure for this sale can be found here. Insiders have sold a total of 35,340 shares of company stock valued at $3,559,683 over the last three months. Company insiders own 18.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of AVXS. Nationwide Fund Advisors boosted its position in AveXis by 9.0% during the 1st quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock worth $262,000 after acquiring an additional 284 shares during the last quarter. Amalgamated Bank boosted its position in AveXis by 19.6% during the 3rd quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock worth $308,000 after acquiring an additional 523 shares during the last quarter. Parametric Portfolio Associates LLC boosted its position in AveXis by 2.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 20,943 shares of the company’s stock worth $1,721,000 after acquiring an additional 598 shares during the last quarter. American International Group Inc. boosted its position in AveXis by 26.7% during the 1st quarter. American International Group Inc. now owns 3,521 shares of the company’s stock worth $268,000 after acquiring an additional 742 shares during the last quarter. Finally, Seven Bridges Advisors LLC boosted its position in AveXis by 49.4% during the 2nd quarter. Seven Bridges Advisors LLC now owns 2,557 shares of the company’s stock worth $210,000 after acquiring an additional 846 shares during the last quarter. 94.84% of the stock is owned by institutional investors and hedge funds.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.